Medicamen Biotech Ltd
Ticker: MEDICAMEQ
Decent
68/100
☆ Add to Watchlist
Investing Reference
Price
376.35
Market Cap
510.44
Debt/Equity
0.1585
ROE %
3.381
PB
2.3959
Promoter %
40.457
Pledge %
0.000
1Y Rev Growth %
-7.074
5Y Rev Growth %
5.781
NP Margin %
4.206
NP Margin 5Y Avg %
8.802
Trading Reference
1M Return %
22.521
6M Return %
-12.983
1Y Return %
-29.818
% Away 52W High
67.397
% Away 52W Low
28.469
Daily Volume
74453
Investment Verdict
Hold
Score 61/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 33/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
Summary
Medicamen Biotech Ltd shows potential for growth in the pharmaceutical sector with a strong product pipeline.
✅ Positives
- Diverse product portfolio in generics and APIs
- Strong revenue growth over the past year
- Robust R&D capabilities enhancing innovation
⚠️ Negatives
- High competition in the pharmaceutical market
- Regulatory challenges affecting product approvals
- Dependence on a few key clients for revenue
Verdict
Moderate growth potential with some risks.
Recommendation: Consider buying on dips for long-term gains.
Upside Probability: 25% | Downside Probability: 15%
Last generated: 30/10/2025
More Options
P
Pavna Industries Ltd
Pavna Industries Ltd shows potential for growth in a favorable sector, but faces challenges in profitability and valuation metrics.
View details
M
Moneyboxx Finance Ltd
Moneyboxx Finance Ltd shows potential for growth but faces several challenges that could impact its performance.
View details
R
RBM Infracon Ltd
RBM Infracon Ltd shows potential in a growing sector but faces significant risks and inconsistencies in financial performance.
View details
I
Infollion Research Services Ltd
Infollion Research Services Ltd shows potential but faces challenges in growth and profitability metrics. Caution is advised for investors.
View details
D
Dhanashree Electronics Ltd
Dhanashree Electronics Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment.
View details
M
Mirza International Ltd
Mirza International Ltd presents a risky investment opportunity due to inconsistent growth and profitability metrics, alongside weak market sentiment.
View details
K
Kothari Products Ltd
Kothari Products Ltd shows potential but faces challenges in growth consistency and market sentiment.
View details
M
Mold-Tek Technologies Ltd
Mold-Tek Technologies Ltd shows potential for growth but faces challenges in profitability and valuation. Investors should be cautious.
View details
N
Nova Agritech Ltd
Nova Agritech Ltd shows potential in a growing sector, but faces challenges in profitability and execution risks.
View details
O
Orient Ceratech Ltd
Orient Ceratech Ltd shows potential but faces significant challenges in growth and profitability metrics. Caution is advised.
View details
C
Career Point Edutech Ltd
Career Point Edutech Ltd shows potential in a growing sector but faces significant challenges in execution, profitability, and valuation, making it a risky investment.
View details
M
Manaksia Ltd
Manaksia Ltd shows potential in a growing sector but faces challenges in profitability and market sentiment.
View details
B
Bedmutha Industries Ltd
Bedmutha Industries Ltd shows potential but faces challenges in growth consistency and profitability metrics. Caution is advised.
View details
A
Albert David Ltd
While Albert David Ltd operates in a promising sector, its inconsistent growth and valuation concerns suggest caution for investors.
View details
O
Osia Hyper Retail Ltd
Osia Hyper Retail Ltd faces significant challenges in growth and profitability, with high valuation metrics and weak market sentiment. Caution is advised for potential investors.
View details
G
Goel Construction Company Ltd
Goel Construction Company Ltd presents several risks that outweigh its potential, making it a risky investment at this time.
View details
Business Overview
Medicamen Biotech Ltd is a prominent Indian pharmaceutical company dedicated to manufacturing high-quality generic and specialty medicines. Catering primarily to healthcare providers and patients, the company plays a crucial role in enhancing access to affordable healthcare solutions. With a strong focus on research and development, Medicamen is committed to innovation and sustainability in the pharmaceutical sector.
- Established leader in the Indian pharmaceutical market
- Wide range of generic and specialty medicines
- Strong commitment to quality and compliance
- Focus on research and development for innovative solutions
- Contributing to affordable healthcare access in India
Investment Thesis
Medicamen Biotech Ltd stands out as a compelling investment due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. These factors position the company for sustained growth and profitability in the evolving pharmaceutical landscape.
- Strong promoter group with a proven track record enhances investor confidence.
- Expansion into digital services presents a robust growth runway.
- Valuation metrics indicate Medicamen is attractively priced relative to industry peers.
- Diversified product portfolio mitigates risks and enhances revenue streams.
- Commitment to innovation positions the company favorably for future market demands.
Opportunity vs Risk
Opportunities
- Growing demand for biopharmaceuticals
- Strong R&D pipeline
- Expansion into international markets
- Government support for biotech sector
Risks ⚠️
- Regulatory challenges
- High competition in industry
- Dependence on key patents
- Market volatility impacts stock price
Peer Perspective
Medicamen Biotech Ltd trades at a discount compared to peers like Sun Pharmaceutical and Lupin, primarily due to margin pressures. A stable margin improvement could trigger a rerating, aligning its valuation more closely with industry leaders.
Future Outlook
Medicamen Biotech Ltd is well-positioned for growth, driven by its robust pipeline and expanding market presence; however, successful execution and effective cost control will be crucial to fully realize its potential.
AI FAQs for Retail Users
- Q: What does Medicamen Biotech Ltd do?A: Medicamen Biotech Ltd is involved in manufacturing and marketing pharmaceutical products, including generic medicines.
- Q: Is Medicamen Biotech Ltd a good investment?A: Investing depends on individual financial goals and market conditions. Research thoroughly before making decisions.
- Q: What are the risks of investing in Medicamen Biotech Ltd?A: Risks include market volatility, regulatory changes, and company-specific factors that may affect performance.
- Q: How can I buy shares of Medicamen Biotech Ltd?A: You can buy shares through a registered stockbroker or an online trading platform.
- Q: What is the company's growth outlook?A: Growth outlook can vary based on market conditions and company performance. Monitor news and reports for updates.
📊 Stock Investment Checklist (100 Points)
Medicamen Biotech Ltd • Updated: 2025-09-17 14:41:41
-
10BusinessHighPharmaceutical sector shows growth potential, but competition is high.
-
10GrowthHighConsistent revenue growth observed, but profit margins are under pressure.
-
10ProfitabilityHighROE and ROCE are decent, but OCF is fluctuating.
-
8ValuationHighP/E ratio is higher than industry average, indicating potential overvaluation.
-
7BalanceHighModerate debt levels, but liquidity ratios are satisfactory.
-
6GovernanceGoodPromoter holding is stable, but some concerns over pledging.
-
5DriversGoodGrowth drivers exist, but execution risks are significant.
-
5TechnicalsGoodMarket sentiment is mixed, with low liquidity.
Final Score & Verdict
Score 68 / 100
• Decent
Medicamen Biotech Ltd shows potential for growth but faces challenges in profitability and valuation. Caution is advised.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 65/100
- Governance: 60/100
- Market Confidence: 68/100